Article: Navigating CAR T Delivery In Autoimmune Indications: Impact & Opportunity
Recent successes of CAR T-cell therapy in oncology have spurred further interest and research into its potential for treating autoimmune diseases, a significant unmet need in life sciences. Yet, to succeed in this highly competitive landscape, biotechs must address challenges in manufacturing and scalability. Explore the impact of CAR T-cell therapies, the obstacles faced, and the future strategies for success, as they discuss:
- Promising results from a study on CAR T-cell therapy
- Importance of site design, specialist expertise and communication
- Difficulties around manufacturing and scalability
- Vital role of industry partnerships, geographical expansion and community organizations
Advancements in Oncology: A New Wave of Technology-Driven Therapeutics
Expert panellists address the key trends and challenges shaping the future of oncology, as they explore:
- How innovations are shaping how later-line treatments are used, and the impact on the patient experience
- Challenges of CAR T-cell therapies, and the benefits of reviving older therapies such as ADCs and bAB
- Pricing pressures and negotiation
- Strategies for driving operational excellence
- Shaking old habits in patient diversity
- Future uses of AI and ML in oncology, such as predicting the impact of drugs on certain subgroups
Article: Advances and challenges in the development of ADCs
Antibody-Drug Conjugates (ADCs) are notoriously tricky to develop, due to their delicate nature and the barriers facing their delivery. Andreas Dreps, Senior Vice President, Drug Development Services at ICON Biotech, highlights key obstacles in the development of ADCs and why the future remains bright for this targeted therapy, as he explores:
- Tumor heterogeneity, resistance and off-target effects
- Delicate nature of ADCs
- Need for highly refined manufacturing protocols
- Advances in linker chemistry, design and manufacturing of mABs
- ADCs as a neoadjuvant therapy in breast cancer
Roundtable Report: Overcoming Obstacles and Seizing Opportunities in Early Phase Biotech Research
In early stage drug development, biotechs face a multitude of challenges, from protocol development to generate the right scientific data required for further investment, to compliance and regulatory requirements, and the identification of strategic partnerships. In this report, discover insights from leading biotechs on:
- Different challenges of each development stage
- CRO selection criteria and scoring tools
- Additional CRO value vs. traditional value proposition
eBook: Developing innovative treatments for CNS disorders
The CNS therapeutic solutions market is witnessing huge growth, due to the aging global population and a surge in R&D. But it's not all plain sailing - in order to improve patient outcomes, researchers, stakeholders and regulatory bodies must address a range of complex challenges posed by these neurological and psychiatric disorders.
- Role of Digital Therapeutics in Central Nervous System Clinical Trials
- For Psychedelics, US FDA Is Open To Creative Thinking But Firm On Approval Standards
- Schizophrenia, Depression And Neuropathy: What’s Coming In 2024
- CGT Is In Its Infancy For CNS Disorders, But Technical Strides Being Made
- Pioneering Partnerships And Novel Trial Design Are Reshaping Repurposing In The CNS Space
Article: Increasing Rare Disease Awareness Brings Promise To Orphan Drug Innovation
Orphan drug innovation has gone from strength to strength, propelled by advances in genetic medicine, such as mRNA therapies. However, challenges remain in patient identification and carrying out small-scale complex clinical trials. In this article, Will Maier, VP and Head of Centre for Rare Disease, ICON Biotech, explores the challenges and the necessary solutions to advance rare disease drug development in today’s dynamic landscape.
- Identifying patient populations
- Role of patient advocacy organizations
- Regulatory complexity
- Reimbursement concerns
- CRO partnerships
Whitepaper: A multifaceted risk factor: Addressing obesity’s impact across the disease spectrum
Obesity is a growing health concern worldwide, with at least 2.8 million people dying each year as a result of the disease. Additionally, the number of individuals living with obesity continues to increase annually across age, gender and geographic location. A complex condition, obesity has implications in inflammatory, metabolic and cardiovascular health — which, together, mean that advancing the treatment of obesity also means accounting for its relationships with other physiological systems and health conditions.
- The foundational physiology and drivers of obesity
- How obesity impacts inflammatory, metabolic and cardiovascular health
- Current approaches to treating obesity
- Unique challenges and approaches in participant recruitment and retention for obesity-related clinical trials
2023 biotech sector survey
Since 2022, biotech has been grappling with a severe funding challenge after a period of robust investment, with both venture capital and public funding drying up.
In a recent report, conducted in association with ICON, we surveyed 133 influential decision-makers on their innovative strategies to navigate the challenges of today’s cash constraints.
Download this report to discover in-depth perspectives from leading decision-makers, on a range of multifaceted challenges, such as:
- How funding changed in 2022
- How cash constraints are shaping biotech
- Managing the complexity of R&D
- Partnering to accelerate biotech innovation
Meeting Milestones Through Effective Biotech Trial Strategies Episode 1
Discover the key challenges facing clinical trial delivery and the current trends and solutions required to optimize efficiency and enhance results.
Meeting Milestones Through Effective Biotech Trial Strategies Episode 2
Explore the latest trends in biotech funding, the strategies for successful alignment with investment priorities, and the supportive role of CROs in the process.
Inspire. Connect. Innovate.
